COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03777410
Recruitment Status : Recruiting
First Posted : December 17, 2018
Last Update Posted : February 21, 2020
Dana-Farber Cancer Institute
Massachusetts General Hospital
Weill Medical College of Cornell University
Icahn School of Medicine at Mount Sinai
City of Hope Comprehensive Cancer Center
Emory University
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Travera LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : February 2021